Last reviewed · How we verify

Passiflora incarnata

Nutricion Medica S.L. · FDA-approved active Small molecule

Passiflora incarnata contains alkaloids and flavonoids that modulate GABAergic and monoaminergic neurotransmission to produce anxiolytic and sedative effects.

Passiflora incarnata contains alkaloids and flavonoids that modulate GABAergic and serotonergic neurotransmission to produce anxiolytic and sedative effects. Used for Anxiety and nervousness, Insomnia and sleep disorders, Restlessness.

At a glance

Generic namePassiflora incarnata
Also known asPascoflair 425mg coated tablets
SponsorNutricion Medica S.L.
Drug classHerbal anxiolytic/sedative
TargetGABA receptors, serotonin receptors (non-selective)
ModalitySmall molecule
Therapeutic areaPsychiatry/Neurology
PhaseFDA-approved

Mechanism of action

The plant extract acts as a mild central nervous system depressant, primarily through enhancement of GABA signaling and modulation of serotonin and dopamine pathways. These mechanisms reduce anxiety, promote relaxation, and improve sleep quality. The active constituents include harmaline, harmine, and various flavonoids that contribute to its calming properties.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results